REFERENCES
1. Lassaletta AD, Chu LM, Sellke FW. Therapeutic neovascularization for coronary disease: current state and future prospects. Basic Res Cardiol 2011;106:897-909.
2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2020;41:407-77.
3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
5. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.
6. Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci 2019;4:15-26.
7. Baker HE, Kiel AM, Luebbe ST, et al. Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol 2019;114:25.
8. Sayour AA, Korkmaz-Icöz S, Loganathan S, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med 2019;17:127.
9. Sabe SA, Xu CM, Sabra M, et al. Canagliflozin improves myocardial perfusion, fibrosis, and function in a swine model of chronic myocardial ischemia. J Am Heart Assoc 2023;12:e028623.
10. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-73.
11. Kubota A, Takano H, Wang H, et al. DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. J Mol Cell Cardiol 2016;91:72-80.
12. Bostick B, Habibi J, Ma L, et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism 2014;63:1000-11.
13. Sabe SA, Harris DD, Broadwin M, et al. Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: a pilot study. Physiol Rep 2023;11:e15744.
14. Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Cardiovasc Diabetol 2023;22:54.
15. Lyu YS, Oh S, Kim JH, Kim SY, Jeong MH. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus. Cardiovasc Diabetol 2023;22:185.
16. Oh M, Choi JH, Kim SO, et al. Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease. Nucl Med Commun 2021;42:972-8.
17. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2022;145:e895-1032.
18. Potz BA, Scrimgeour LA, Pavlov VI, Sodha NR, Abid MR, Sellke FW. Extracellular vesicle injection improves myocardial function and increases angiogenesis in a swine model of chronic ischemia. J Am Heart Assoc 2018;7:e008344.
19. Scrimgeour LA, Potz BA, Aboul Gheit A, et al. Extracellular vesicles promote arteriogenesis in chronically ischemic myocardium in the setting of metabolic syndrome. J Am Heart Assoc 2019;8:e012617.
20. Aboulgheit A, Karbasiafshar C, Zhang Z, et al. Lactobacillus plantarum probiotic induces Nrf2-mediated antioxidant signaling and eNOS expression resulting in improvement of myocardial diastolic function. Am J Physiol Heart Circ Physiol 2021;321:H839-49.
21. Elmadhun NY, Lassaletta AD, Chu LM, Liu Y, Feng J, Sellke FW. Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome. J Thorac Cardiovasc Surg 2012;144:1486-93.
22. Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep 2017;7:16878.
23. Paolisso P, Bergamaschi L, Gragnano F, et al. Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry. Pharmacol Res 2023;187:106597.
24. Forzano I, Wilson S, Lombardi A, et al. SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opin Investig Drugs 2023;32:839-47.
25. Wu YJ, Wang SB, Wang LS. SGLT2 inhibitors: new hope for the treatment of acute myocardial infarction? Am J Cardiovasc Drugs 2022;22:601-13.
26. Choi JG, Winn AN, Skandari MR, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med 2022;175:1392-400.
27. Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 2022;21:47.
28. Spoladore R, Pinto G, Daus F, Pezzini S, Kolios D, Fragasso G. Metabolic approaches for the treatment of dilated cardiomyopathy. J Cardiovasc Dev Dis 2023;10:287.
29. Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH. Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease. J Obes Metab Syndr 2019;28:254-61.
30. Banerjee D, Sabe SA, Xing H, et al. Canagliflozin improves coronary microvascular vasodilation and increases absolute blood flow to the myocardium independent of angiogenesis. J Thorac Cardiovasc Surg 2023;166:e535-50.
31. Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in the heart. Circ Res 2012;111:800-14.
32. Li X, Liu J, Lu Q, et al. AMPK: a therapeutic target of heart failure-not only metabolism regulation. Biosci Rep 2019;39:BSR20181767.
33. Harris DD, Sabe SA, Xu CM, et al. Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia. Surgery 2024;175:265-70.
34. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med 2008;8:754-67.
35. Mone P, Varzideh F, Jankauskas SS, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension 2022;79:1633-43.
